Clinical Trials in Amiens, France
1 recruiting
Showing 1–20 of 20 trials
Recruiting
Phase 3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC675 enrolled96 locationsNCT07190248
Recruiting
Phase 3
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled234 locationsNCT06966700
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled217 locationsNCT06170788
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.630 enrolled337 locationsNCT06875310
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Breast Cancer
Celcuity Inc674 enrolled203 locationsNCT06757634
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences1,514 enrolled288 locationsNCT05633654
Recruiting
Phase 2
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
UNICANCER354 enrolled44 locationsNCT06078384
Recruiting
Phase 2
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Triple Negative Breast Neoplasms
UNICANCER220 enrolled20 locationsNCT05973864
Recruiting
PRostate Olaparib Real World Evidence Study
Metastatic Castration-resistant Prostate Cancer
AstraZeneca300 enrolled65 locationsNCT06031805
Recruiting
Not Applicable
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie100 enrolled46 locationsNCT05122806
Recruiting
A Randomised Clinical Investigation to Assess Efficacy of Low Volume Transanal Irrigation by Qufora® IrriSedo MiniGo Versus Conservative Treatment for Low Anterior Resection Syndrome Patients
Rectal CancerLARS - Low Anterior Resection SyndromeGastroenterology
Qufora A/S78 enrolled9 locationsNCT06923150
Recruiting
Phase 2
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
HER2-positive Breast Cancer
Institut Curie66 enrolled13 locationsNCT05955170
Recruiting
Phase 2Phase 3
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
Metastatic NSCLC
Intergroupe Francophone de Cancerologie Thoracique1,360 enrolled44 locationsNCT05255302
Recruiting
Not Applicable
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Hepatocellular CarcinomaMetastatic Colorectal CancerNeuroendocrine Tumors+2 more
UNICANCER330 enrolled29 locationsNCT05443087
Recruiting
Not Applicable
Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer
Breast CancerFatigue
Centre Francois Baclesse354 enrolled10 locationsNCT05241405
Recruiting
Phase 2
FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
Large Cell Neuroendocrine Carcinoma of the Lung
Centre Leon Berard80 enrolled31 locationsNCT06393816
Recruiting
Not Applicable
Spa Therapy for Upper or Lower Limb Lymphoedema
Breast CancerProstate CancerLymphoma+3 more
Association Francaise pour la Recherche Thermale160 enrolled13 locationsNCT03580109